Oncolytic vaccinia virus: A silver bullet?

Expert Review of Vaccines

Volumn 9, Issue 12, 2010, Pages 1353-1356

  Lusky, Monika ^a   Erbs, Philippe ^a   Foloppe, Johann ^a   Acres, R Bruce ^a  

^a TRANSGENE S A   (France)

Author keywords

cancer gene therapy; cancer immunotherapy; oncolytic virus; tumor targeted suicide gene expression

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; FLUOROURACIL; JX 594; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; DRUG MECHANISM; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE THERAPY; TUMOR GROWTH; VACCINIA; VIRUS STRAIN;

HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINIA VIRUS;

EID: 78649519141     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.137     Document Type: Editorial

References (27)

1. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13(Suppl. 1), 5-13 (2008).
2. Simmons O, Magee M, Nemunaitis J. Current vaccine updates for lung cancer. Expert Rev. Vaccines 9(3), 323-335 (2010).
3. Coley W. Late results of the treatment of inoperable sarcoma by the mixed toxins of Erysipelas and Bacillus prodigiosus. Am. J. Med. Sci. 131, 375-428 (1906).
4. Newman W, Southam CM. Virus treatment in advanced cancer. A pathological study of ffty seven cases. Cancer 7(1), 106-118 (1954).
5. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15(4), 651-659 (2007).
6. Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med. Oncol. Tumor Pharmacother. 9(4), 169-171 (1992).
7. Scoggin SD, Sivanandham M, Sperry RG, Wallack MK. Active specifc adjuvant immunotherapy with vaccinia melanoma oncolysate. Ann. Plast. Surg. 28(1), 108-109 (1992).
8. Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial. Lancet Oncol. 9(6), 533-542 (2008).
9. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9(1), 64-71 (2009).
10. Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 25(1), 21-28 (1983).
11. Mackett M, Smith GL, Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49(3), 857-864 (1984).
12. Buller R, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317, 813-815 (1985).
13. Kaplan C. Vaccinia virus: a suitable vehicle for recombinant vaccines? Arch. Virol. 106(1-2), 127-139 (1989).
14. Acres B, Dott K, Stefani L, Kieny MP. Directed cytokine expression in tumor cells in vivo using recombinant vaccinia virus. Ther. Immunol. 1(1), 17-23 (1994).
15. Acres B, Stefani L, Dott K, Kieny MP. Delivery of cytokine genes to tumor cells in vivo using recombinant vaccinia virus vectors-cytokine cDNA gene expression in vaccinia virus vector; tumor-bearing mouse injection for potential cancer cytokine-mediated gene therapy (conference abstract). Cancer Gene Ther. 1(4), 308 (1994).
16. Gahéry-Ségard H, Molinier-Frenkel V, Le Boulaire C et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest. 100(9), 2218-2226 (1997).
17. Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, Szalay AA. The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol. Immunother. 58(9), 1355-1362 (2009).
18. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest. New Drugs 18(4), 299-313 (2000).
19. Noordhuis P, Holwerda U, van der Wilt CL et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann. Oncol. 15(7), 1025-1032 (2004).
20. Okamoto M, Kasetani H, Kaji R et al. cis-Diamminedichloroplatinum and 5-fuorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol. Immunother. 47(4), 233-241 (1998).
21. Vincent J, Mignot G, Chalmin F et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052-3061 (2010).
22. Gnant MF, Puhlmann M, Alexander HR Jr, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fuorocytosine leads to tumor-specifc gene expression and prolongation of survival in mice. Cancer Res. 59(14), 3396-3403 (1999).
23. Chalikonda S, Kivlen MH, O'Malley ME et al. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 15(2), 115-125 (2008).
24. Erbs P, Regulier E, Kintz J et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 60(14), 3813-3822 (2000).
25. Foloppe J, Kintz J, Futin N et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 15(20), 1361-1371 (2008).
26. McCart JA, Ward JM, Lee J et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61(24), 8751-8757 (2001).
27. Guo ZS, Naik A, O'Malley ME et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. 65(21), 9991-9998 (2005).